Polycystic Ovary Syndrome Clinical Trial
— CNPOfficial title:
C Type Natriuretic Peptide and Polycystic Ovary Syndrome
NCT number | NCT04006171 |
Other study ID # | CNP |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 15, 2019 |
Est. completion date | September 1, 2020 |
Verified date | October 2021 |
Source | Near East University, Turkey |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Recent studies have shown that C natriuretic peptide is produced from granulosa cells, increasing cumulative guanosine monophosphate (cGMP) production by affecting cumulus cells through natriuretic peptide receptors. It is suggested that produced cGMP maintains the transport of oocytes via the gap junctions and leads to a continuous increase in cyclic adenosine monophosphate (cAMP) levels in the oocyte. An important role of increased internal cAMP levels in the oocyte is shown to suppress meiotic progression. Deoxyribonucleic acid studies in animals have shown that expression of the natriuretic peptide precursor increases during the periovulatory period and shows that this increase decreases rapidly after luteinizing hormone / human chorionic gonadotropin (hCG) stimulation.Human studies have shown that after ovulation induction, the CNP level in follicular fluid decreases following ovulatory dose of hCG.Polycystic ovary syndrome (PCOS) is the most common endocrine disease in the reproductive period, characterized by hyperandrogenism, oligo-anovulation, and polycystic ovarian morphology on ultrasonography, and in an animal study investigating the relationship between CNP and PCOS, serum CNP levels were increased in polycystic ovary syndrome.CNP serum level is thought to show differences between healthy women and women with polycystic ovary syndrome.
Status | Completed |
Enrollment | 90 |
Est. completion date | September 1, 2020 |
Est. primary completion date | September 1, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: - PCOS defined according to Rotterdam criteria - Healthy normal menstruating women Exclusion Criteria: - Diabetes mellitus - Cardiavascular disease - Renal disease - Any drug usage - Smoking - Pregnancy |
Country | Name | City | State |
---|---|---|---|
Cyprus | Near East University Faculty of Medicine | Nicosia |
Lead Sponsor | Collaborator |
---|---|
Near East University, Turkey |
Cyprus,
Hiradate Y, Hoshino Y, Tanemura K, Sato E. C-type natriuretic peptide inhibits porcine oocyte meiotic resumption. Zygote. 2014 Aug;22(3):372-7. doi: 10.1017/S0967199412000615. Epub 2013 Jan 18. — View Citation
Kawamura K, Cheng Y, Kawamura N, Takae S, Okada A, Kawagoe Y, Mulders S, Terada Y, Hsueh AJ. Pre-ovulatory LH/hCG surge decreases C-type natriuretic peptide secretion by ovarian granulosa cells to promote meiotic resumption of pre-ovulatory oocytes. Hum Reprod. 2011 Nov;26(11):3094-101. doi: 10.1093/humrep/der282. Epub 2011 Aug 23. — View Citation
Lee KB, Zhang M, Sugiura K, Wigglesworth K, Uliasz T, Jaffe LA, Eppig JJ. Hormonal coordination of natriuretic peptide type C and natriuretic peptide receptor 3 expression in mouse granulosa cells. Biol Reprod. 2013 Feb 21;88(2):42. doi: 10.1095/biolreprod.112.104810. Print 2013 Feb. — View Citation
Nogueira D, Albano C, Adriaenssens T, Cortvrindt R, Bourgain C, Devroey P, Smitz J. Human oocytes reversibly arrested in prophase I by phosphodiesterase type 3 inhibitor in vitro. Biol Reprod. 2003 Sep;69(3):1042-52. Epub 2003 May 28. — View Citation
Norris RP, Ratzan WJ, Freudzon M, Mehlmann LM, Krall J, Movsesian MA, Wang H, Ke H, Nikolaev VO, Jaffe LA. Cyclic GMP from the surrounding somatic cells regulates cyclic AMP and meiosis in the mouse oocyte. Development. 2009 Jun;136(11):1869-78. doi: 10.1242/dev.035238. — View Citation
Reis AM, Honorato-Sampaio K. C-type natriuretic peptide: a link between hyperandrogenism and anovulation in a mouse model of polycystic ovary syndrome. Clin Sci (Lond). 2018 May 8;132(9):905-908. doi: 10.1042/CS20171491. Print 2018 May 16. — View Citation
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004 Jan;81(1):19-25. — View Citation
Thomas RE, Armstrong DT, Gilchrist RB. Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation. Dev Biol. 2002 Apr 15;244(2):215-25. — View Citation
Tsafriri A, Chun SY, Zhang R, Hsueh AJ, Conti M. Oocyte maturation involves compartmentalization and opposing changes of cAMP levels in follicular somatic and germ cells: studies using selective phosphodiesterase inhibitors. Dev Biol. 1996 Sep 15;178(2):393-402. — View Citation
Vaccari S, Weeks JL 2nd, Hsieh M, Menniti FS, Conti M. Cyclic GMP signaling is involved in the luteinizing hormone-dependent meiotic maturation of mouse oocytes. Biol Reprod. 2009 Sep;81(3):595-604. doi: 10.1095/biolreprod.109.077768. Epub 2009 May 27. — View Citation
Wang X, Wang H, Liu W, Zhang Z, Zhang Y, Zhang W, Chen Z, Xia G, Wang C. High level of C-type natriuretic peptide induced by hyperandrogen-mediated anovulation in polycystic ovary syndrome mice. Clin Sci (Lond). 2018 Apr 6;132(7):759-776. doi: 10.1042/CS20171394. Print 2018 Apr 16. — View Citation
Zhang M, Su YQ, Sugiura K, Xia G, Eppig JJ. Granulosa cell ligand NPPC and its receptor NPR2 maintain meiotic arrest in mouse oocytes. Science. 2010 Oct 15;330(6002):366-9. doi: 10.1126/science.1193573. — View Citation
* Note: There are 12 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Serum CNP Levels of PCOS and Healthy Participants | The comparison of serum levels of C type natriuretic peptide among PCOS and healthy women | Second or Third Day of Menstruation | |
Primary | Roc Curve of CNP | We made a cut off value estimation for the diagnosis of PCOS by serum CNP levels using Receiver operator characteristics. The ROC curve incorporates both sensitivity (true positive rate) and specificity (true negative rate) providing a single assessment incorporating both measures. The higher the total area under the curve, the greater the predictive power of the CNP for diagnosing PCOS | Second or Third Day of Menstruation | |
Secondary | Comparison of FSH and LH of PCOS and Healthy Women | Serum FSH and LH of PCOS and healthy women were compared | Second or Third Day of Menstruation | |
Secondary | Serum Estradiol Levels of PCOS and Healthy Women | Serum Estradiol levels of PCOS and Healthy Women were compared | Second or Third Day of Menstruation | |
Secondary | Serum Tiroid Stimulating Hormone of PCOS and Healthy Women | serum tiroid stimulating hormone of PCOS and healthy women were compared | Second or Third Day of Menstruation | |
Secondary | Serum Prolactin Levels of PCOS and Healthy Women | serum prolactin levels of PCOS and healthy women were compared | Second or Third Day of Menstruation | |
Secondary | Serum Androstenedione Levels of PCOS and Healthy Women | Serum Androstenedione Levels of PCOS and Healthy Women were compared | Second or Third Day of Menstruation | |
Secondary | Serum Dehydroepiandrosterone Sulfate (DHEAS) Levels of PCOS and Healthy Women | Serum dehydroepiandrosterone sulfate (DHEAS) Levels of PCOS and Healthy Women were compared | Second or Third Day of Menstruation | |
Secondary | Serum Total Testosterone Levels of PCOS and Healthy Women | Serum Total Testosterone Levels of PCOS and Healthy Women were compared | Second or Third Day of Menstruation | |
Secondary | Serum Free Testosterone Levels of PCOS and Healthy Women | Serum Free Testosterone Levels of PCOS and Healthy Women were compared | Second or Third Day of Menstruation | |
Secondary | Serum Sex Hormone Binding Globulin Levels of PCOS and Healthy Women | Serum Sex Hormone Binding Globulin Levels of PCOS and Healthy Women were compared | Second or Third Day of Menstruation | |
Secondary | Free Androgen Index of Participants | Free androgen index of participants were compared. It was calculated with the formula 100XTotal testosterone/Sex hormone binding globulin | Second or Third Day of Menstruation | |
Secondary | Serum Glucose, Total Cholesterol and Triglycerides Levels of Participants | Serum glucose, total cholesterol and triglycerides levels of participants were compared | Second or third day of menstruation and morning fasting | |
Secondary | High Density Lipoprotein and Low Density Lipoprotein Levels of Participants | High density lipoprotein and low density lipoprotein levels of participants were compared | Second or Third Day of Menstruation-morning fasting | |
Secondary | Serum Insulin Levels of Participants | Serum Insulin Levels of Participants were compared | Second or Third Day of Menstruation-morning fasting | |
Secondary | Homeostatic Model Assessment of Insulin Resistance of Participants | homeostatic model assessment of insulin resistance of participants were compared. The calculation was made with formula Glucose X Insulin/405. | Second or Third Day of Menstruation-morning fasting |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03142633 -
MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
|
||
Completed |
NCT06158932 -
A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Completed |
NCT04932070 -
Berberine and Polycystic Ovary Syndrome
|
N/A | |
Suspended |
NCT03652987 -
Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
|
||
Completed |
NCT03480022 -
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
|
Phase 3 | |
Active, not recruiting |
NCT03043924 -
Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS)
|
N/A | |
Completed |
NCT05246306 -
Aerobic Capacity and Physical Fitness Level of Adolescents With PCOS
|
||
Completed |
NCT05981742 -
Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS
|
Phase 2 | |
Completed |
NCT05702957 -
Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT05029492 -
Effect of Visceral Manipulation on PCOS
|
N/A | |
Completed |
NCT02924025 -
Motivational Interviewing as an Intervention for PCOS
|
N/A | |
Not yet recruiting |
NCT02255578 -
Endobarrier Treatment in Women With PCOS
|
Phase 3 | |
Withdrawn |
NCT01638988 -
Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin
|
Phase 3 | |
Not yet recruiting |
NCT00883259 -
Metformin and Gestational Diabetes in High-risk Patients: a RCTs
|
Phase 4 | |
Completed |
NCT02098668 -
Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON
|
N/A | |
Completed |
NCT01462864 -
Development of a Structured Education Programme for Women With Polycystic Ovary Syndrome
|
N/A | |
Recruiting |
NCT01431352 -
Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS)
|
N/A | |
Completed |
NCT00989781 -
Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome
|
N/A |